Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This is much more than "commenced"

<< Previous

Bullboard Posts

Next >>

Comment by Arbourmarkon Jun 28, 2021 10:35am

125 Views

Post# 33459420

RE:RE:RE:This is much more than "commenced"

The reality the longer this dance with big pharma goes the more ammunition we add to our valuation. It would be in big pharma's best interest to hammer out a deal now versus letting Antibe produce more stellar results. I personally feel another Nuance structured partnership at a higher valuation will be the next big news release.

MrMugsy wrote:

GameChangerBet wrote: Perhaps they're close to a deal and want to partner up for the start of Phase 3.
Could be a reason for the start to be slightly pushed out, buy some more time to finalize a deal.
Just speculating between the lines..

Actuarial wrote: "we’re now entering confidential discussions for the large markets"

Yes - I'm sure they would like to conclude an agreement.
All depends how many companies are in the running and how far the valuations are from ATE's expected payout.

I think you could very quickly get there if two sides can agree to a valuation based on milestone payments, up to and including a successful P3 (where P3 will still be run to Antibe's gameplan).

A deal could happen at anytime or at no time in 2021. Sure, the odds are more likely for 2022 but we just don't know.